Zenas BioPharma Inc.

6 days ago · marketbeat.com

Zenas BioPharma NASDAQ: ZBIO outlined development plans for obexelimab in systemic lupus erythematosus (SLE) and ZB021, an investigational oral IL-17AA/AF inhibitor, during an R&D event ahead of clinical data expected later in the quarter.

9 days ago · seekingalpha.com

Zenas BioPharma, Inc. (ZBIO) R&D Event: Obexelimab in SLE and ZB021 Development Transcript

13 days ago · zacks.com

The mean of analysts' price targets for Zenas BioPharma, Inc. (ZBIO) points to a 77.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

1 month ago · globenewswire.com

WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that it will host a virtual R&D event on Tuesday, October 27, 2026, from 8:00 – 9:30 a.m. ET.

1 month ago · seekingalpha.com

Zenas BioPharma (ZBIO) is advancing obexelimab for IgG4-RD, with FDA acceptance and a May 2027 PDUFA date, positioning as a long-term maintenance therapy. ZBIO maintains a sizable cash runway, with pro forma balances covering operations into late 2028, though financing risk remains if FDA approval is delayed. Obexelimab's non-depleting B cell inhibition offers a differentiated safety profile versus Uplizna, targeting chronic use in older patients and potentially expanding the addressable market.

1 month ago · seekingalpha.com

Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript

2 months ago · seekingalpha.com

Zenas BioPharma, Inc. (ZBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · seekingalpha.com

Zenas BioPharma, Inc. (ZBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

2 months ago · globenewswire.com

WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that it will host an Obexelimab IgG4-RD Investor Event virtually on Tuesday, September 29, 2026, from 8:00 – 9:30 a.m. ET.

2 months ago · globenewswire.com

WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced management's presentations at the following investor conferences: Citi Biopharma Back to School Conference on Wednesday, September 9, 2026, at 4:20 p.m.